Company profile

PFE stock data

(
)

Calendar

8 Aug 19
23 Oct 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue 13.26B 13.12B 13.98B 13.3B
Net income 5.05B 3.88B -393M 4.11B
Diluted EPS 0.89 0.68 -0.05 0.69
Net profit margin 38.04% 29.61% -2.81% 30.94%
Operating income* 4.52B 4.68B -588M 4.48B
Net change in cash -153M 798M -2.42B 855M
Cash on hand 1.78B 1.94B 1.14B 3.56B
Cost of revenue 2.58B 2.43B 3.08B 2.69B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 53.65B 52.55B 52.82B
Net income 11.15B 21.31B 7.22B 6.96B
Diluted EPS 1.87 3.52 1.17 1.11
Net profit margin 20.79% 40.55% 13.66%
Operating income* 13.17B 13.53B 9.51B 10.14B
Net change in cash -203M -1.25B -1.05B 298M
Cash on hand 1.14B 1.34B 2.6B 3.64B
Cost of revenue 11.25B 11.23B 12.32B 9.65B

Financial data from Pfizer earnings reports. *Asterisk values are approximate.

Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: AA, acid, andNew, Array, Aurobindo, boxed, bridge, CDK, cervical, cognitive, Colorado, conclusion, confirmed, consumption, contemplated, coupon, CreditWatch, decade, dilated, dual, Endothelial, enterprise, equate, excellence, formation, FORMSFOR, FTC, glioblastoma, hepatocellular, Hurricane, Inline, instance, Lamin, Les, lungcancer, lymphocytic, lymphoma, Maria, mCRC, microscopic, mitigate, notably, notch, NRDL, obligor, opioid, page, patientswith, pembrolizumab, potency, Presidential, pro, protein, rata, RCC, RESET, SAS, secondary, selectin, simultaneously, SmPC, strongest, symptomatic, TEC, thehead, transform, triple, underwritten, Vascular, VEGFR, vigorously, wholly, XBRL
Removed: accompanied, adenocarcinoma, agent, aggressively, alfa, Amgen, antirheumatic, Apixaban, appealing, Asian, bleeding, Blueprint, bolivar, closely, communicate, communicated, consistent, conventional, de, death, DICOM, divested, EEA, epoetin, Epogen, exert, filgrastim, gastric, gastroesophageal, head, improvement, inadequate, Inspector, intolerant, limiting, long, medicinal, methotrexate, mixed, moderately, Neupogen, neuromuscular, neuroscience, observed, occurred, ovarian, overexpressing, Panel, partner, pharmacy, priced, Procrit, publish, RAR, recover, reducing, released, revalue, talazoparib, tanezumab, Trump, vehicle, vote, wrongful